Skip to content

The effect of Baduanjin exercise on cognitive function in patients with post-stroke cognitive impairment:a randomized controlled trial

The effect of Baduanjin exercise on cognitive function in patients with post-stroke cognitive impairment:a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009364
Enrollment
Unknown
Registered
2016-10-10
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive impairment after stroke

Interventions

Baduanjin exercise group:Baduanjin exercise and Basic treatment and Health education
controls:Basic treatment and Health education

Sponsors

Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of stroke (according to the fourth national academic conference on cerebrovascular diseases Diagnostic Criteria for All Kinds of Cerebrovascular Disease), and confirmed by computed tomography or magnetic resonance imaging; 2. With mild cognitive impairment(according to Diagnostic and Statistical Manual Disoeders,5th edition,DSM-V) 3. First ever stroke and within one year poststroke; 4. Aged between 45 to 75 years; 5. Patient should be conscious, with stable vital signs; 6. Safety walk 10 meters or more independently without external force and auxiliary equipment; 7. Signed informed consent to participate in this trial.

Exclusion criteria

Exclusion criteria: 1. Patients who suffer from brain tumor, brain trauma, brain parasite disease, or other diseases that could cause cognitive impairment; 2. Patients with severe language, vision, and/or auditory impairment, or neuropsychiatric disorder precluding cognitive examination; 3. Patients who suffer from diseases related to cognitive impairment confirmed by anamnesis, doctors, or families, or with history of cognitive drug use before stroke 4. Beck Depression Scale-II score >13; 5. Patients with alcohol or drug abuse; 6. Patients with severe illnesses, such as heart, liver, kidney, and endocrine diseases, and hematopoietic system disease; 7. Patients who are included in other clinical trials that would affect the evaluation results of this study.

Design outcomes

Secondary

MeasureTime frame
execution;memory;attention;processing speed;visuospatial skills;dual task gait analysis;

Primary

MeasureTime frame
cognitive function;

Countries

China

Contacts

Public ContactGuohua Zheng

Shanghai University of Medicine & Health Sciences

zhgh_1969@aliyun.com+86 17740887763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026